Activity Summary:
IPF care is shifting fast, and this year brought major data that will influence how clinicians diagnose, monitor, and manage disease in the year ahead. What’s New Doc? End-Of-The-Year Updates on IPF is a focused, high-impact CME activity designed to give pulmonologists, ILD specialists, and multidisciplinary care teams a clear view of the most important 2025 findings and how they translate to practice.

This activity reviews new epidemiologic insights, real-world antifibrotic outcomes, patient-reported challenges, and the latest trial results for emerging therapies expected to shape care in 2026. Steven Nathan, MD guides learners through the evidence with practical takeaways that support better decision making on diagnosis, therapy selection, tolerability management, and quality-of-life improvement.

Activity Summary:
One of the most active areas in HIV research is ART switch strategies in virologically suppressed patients with HIV (PWH). Recent switch studies highlight the use of INSTI-, non-INSTI, and long-acting ART regimens as well as a shifting in strategies–from one of only achieving viral suppression towards also addressing simplification, minimizing long-term toxicities, managing comorbidities, and improving quality of life. This activity is designed to update healthcare professionals with the latest cutting-edge evidence on ART switch strategies in virologically suppressed PWH that were reported in 2025 as well as discuss their implications on patient management trends for 2026.

Activity Summary:
One of the most active areas in HIV research is ART switch strategies in virologically suppressed patients with HIV (PWH). Recent switch studies highlight the use of INSTI-, non-INSTI, and long-acting ART regimens as well as a shifting in strategies–from one of only achieving viral suppression towards also addressing simplification, minimizing long-term toxicities, managing comorbidities, and improving quality of life. This activity is designed to update healthcare professionals with the latest cutting-edge evidence on ART switch strategies in virologically suppressed PWH that were reported in 2025 as well as discuss their implications on patient management trends for 2026.

Activity Summary:
Methamphetamine use is a growing public health concern with serious cardiovascular consequences. One of the most challenging and underrecognized complications is methamphetamine-associated pulmonary arterial hypertension (Meth-APAH), a progressive condition with high morbidity that often presents alongside complex psychosocial and adherence issues.

This on-demand, case-based CME activity equips clinicians with the knowledge and tools to identify, evaluate, and manage Meth-APAH using an evidence-based, multidisciplinary approach.

Activity Summary:
To reinforce key insights from the Transforming ILD Management activity and support real-world application, this resource library offers downloadable materials for quick reference and team-based learning. Designed for busy clinicians, these tools include concise visual summaries, clinical takeaways, and ready-to-share content that complement the podcast and highlights video.

Available Resources:

• Clinical Snippet Highlights
  Concise, one-page summaries of key ILD posters and abstracts presented in Chicago, IL, from October 19-22, 2025, featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.
• Interactive Q&A Summaries
  Concise summaries of expert faculty responses to key questions on ILD diagnosis and management, compiled for easy reference after the program.
• Guideline Updates
  A summary of the latest update to ILD-related guidelines to support evidence-based practice.
• References and Resource Links
  Direct access to featured studies, abstracts, and other key materials cited in the program.
• Accredited Slides
  Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.
• Expert Commentary Transcript
  A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Significant disparities in HIV acquisition risk, access to ART, and viral suppression persist in the United States between racial groups, specific populations, and geographies, among others. Long-acting ART expands existing options for HIV treatment. Further, understanding the appropriate use of ART options along with prevention and management of co-morbidities strategies are critical in the long-term management of HIV.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Pre-exposure prophylaxis (PrEP) provides safe and robust protection again HIV infection in a diversity of populations at risk. In addition, PrEP when used in combination with other approaches has led to reductions in population-level HIV incidence at regional and city levels. This activity will discuss the impact of PrEP on ending the HIV epidemic, benefits and limitations of new and future PrEP options, and strategies to improve sustainable implementation of PrEP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Adolescents are disproportionately affected by HIV, accounting for approximately 1 in 5 new HIV infections in the United States. The expanded options for pre-exposure prophylaxis (PrEP) in adolescents provides clinicians with additional, effective tools to further reduce the risk of HIV transmission in this group. Once diagnosed, youth with HIV are the least likely out of any age group to be linked to care and achieve viral suppression once on ART.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:

COPD care is evolving - are you keeping up? In this four-part podcast series, Drs. Sonali Bose and MeiLan Han share practical insights on personalizing COPD treatment, applying the latest guideline updates, and managing complex cases of dyspnea and exacerbation. Through expert discussion and case-based learning, you’ll gain strategies to confidently navigate therapeutic decision-making and improve patient outcomes.

What You’ll Learn:

• How to apply 2025 GOLD guideline updates to your COPD practice
• Strategies for managing patients with persistent symptoms despite dual or triple therapy
• Biomarker-driven decision-making for recurrent exacerbations
• Real-world case reviews with actionable, expert commentary

Activity Summary:
Chronic obstructive pulmonary disease (COPD) remains a major global health challenge, characterized by significant unmet needs in early diagnosis, personalized management, and coordinated multidisciplinary care. Many patients continue to receive suboptimal, non-guideline-aligned treatment, often leading to poorer outcomes, increased exacerbations, and diminished quality of life.

Join Dr. Bose and Dr. Han as they present key clinical findings in COPD Management. This activity includes four modules:

1. COPD Management
2. Highlights from 2025 Conferences and Publications
3. Persistent Dyspnea Despite Guideline-based Therapy (Case Review)
4. Recurrent Exacerbations in Biomarker-defined Subgroup (Case Review)

Activity Summary:
The field of pulmonary medicine, especially in the management of interstitial lung diseases (ILD), is experiencing a vibrant era of growth with continuous advancements in diagnostic methods and treatment strategies. These progresses are transforming patient care, though the rapid pace of emerging research and the complexities involved in integrating new evidence into clinical practice present unique challenges.

These accredited slides offer key presentations, posters, and abstracts presented in Chicago from October 19-22, 2025, that have important clinical implications for advancing the care of interstitial lung disease (ILD).

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with "what you need to know" podcast episodes from data presented at IDWeek 2025.

Activity Summary:

In this 15-minute podcast, Dr. Steven Nathan reviews clinically significant presentations, posters, and abstracts presented in Chicago from October 19-22, 2025, that offer key insights for improving the diagnosis and management of interstitial lung disease (ILD).

Activity Summary:
The field of pulmonary medicine, especially in the management of interstitial lung diseases (ILD), is experiencing a vibrant era of growth with continuous advancements in diagnostic methods and treatment strategies. These progresses are transforming patient care, though the rapid pace of emerging research and the complexities involved in integrating new evidence into clinical practice present unique challenges.

In this 15-minute video, Dr. Steven Nathan highlights key presentations, posters, and abstracts presented in Chicago from October 19-22, 2025, that have important clinical implications for advancing the care of interstitial lung disease (ILD).

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with "what you need to know" videos from data presented at IDWeek 2025.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clip podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with "what you need to know" videos from data presented at EACS 2025.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with "what you need to know" videos from data presented at EACS 2025.

Activity Summary:

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Activity Summary:

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:

Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This podcast will utilize a case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC. 

Activity Summary:
Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This program will utilize case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC.

Activity Summary:
Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This podcast, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.